The recent series A financing by Bambusa Therapeutics Inc. to fund bispecific antibodies for immunological and inflammatory disorders proved investor faith in the new approach with a proven mechanism.
Researchers from Ileadbms Co. Ltd. presented the discovery and preclinical characterization of IL-21120033, a new CXCR7 agonist being developed for the treatment of inflammatory bowel disease.
Researchers from CJ Bioscience Inc. presented the discovery and preclinical characterization of CJRB-201, a novel microbiome-based therapy for the treatment of inflammatory bowel disease (IBD).
Scientists from the Lebanese American University investigated the role of acetyl-CoA synthetase short chain family member 2 (ACSS2) in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
Researchers from Sunrock Biopharma SL presented preclinical data on SRB-1, a CCR9-depleting antibody aimed to restore immune homeostasis in patients with inflammatory bowel disease.
Investigating the relationship between IL-1 and inflammation in inflammatory bowel disease (IBD), researchers unveiled mesenchyme homeobox 1 (MEOX1), an IL-1-dependent transcription factor that is known to regulate fibrosis in cardiac ischemia that is tied to IBD ulcers and positively expressed in ACKR1+ ECs.
At the recent 2025 congress of the European Crohn’s and Colitis Organisation, researchers from Helixon Therapeutics presented the discovery and preclinical characterization of HXN-1002, a bispecific antibody simultaneously targeting both α4β7 and TL1A that is being investigated as a potential treatment for inflammatory bowel disease.
Anterior gradient 2 (AGR2) is a protein located in the endoplasmic reticulum involved in protein folding and when stressed, it is secreted into the extracellular space and it attracts monocytes, activates fibroblasts and disrupts the epithelial integrity. The relationship between the expression of AGR2 in tissues from patients with inflammatory bowel disease (IBD) was investigated, as well as the efficacy of an anti-AGR2 antibody in murine models of colon inflammation and fibrosis.
Thetis Pharmaceuticals LLC has presented preclinical data on their BLT1 receptor agonist TP-317 as an approach for treating inflammatory bowel disease. BLT1 activation promotes immune homeostasis and repair; oral therapy with TP-317 was investigated in two preclinical models of colitis and ileitis.
In autoimmune diseases such as inflammatory bowel disease (IBD), the function of regulatory CD8 T cells (CD8 Treg) is compromised, in part due to the expression of inhibitory KIR receptors (KIR2DL1/2/3) and insufficient inducible T-cell co-stimulator (ICOS) signaling. Mozart Therapeutics Inc. has discovered MTX-201, a new bispecific antibody targeting inhibitory KIR and ICOS that are co-expressed by CD8 Tregs.
